by In2Pharma | Dec 15, 2022 | News
Europe EMA’s safety committee, PRAC, has concluded its review of medicines containing pholcodine, which are used in adults and children to treat non-productive (dry) cough and, in combination with other active substances, for the treatment of symptoms of...
by In2Pharma | Dec 12, 2022 | News
Europe The Commission Regulation (EU) 2022/2340 amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards green tea extracts containing (-)-epigallocatechin-3-gallate has been published on 30 November 2022. This...
by In2Pharma | Dec 2, 2022 | News
Europe A new questions and answers concerning titanium dioxide was published by the EMA. The Q&A, including five questions, gives guidance about the replacement or removal of titanium dioxide in medicines. Titanium dioxide (E 171) is commonly used in the...
by In2Pharma | Jul 5, 2022 | News
Europe All Marketing authorisation holders (MAHs) should register their Industry Single Point of Contact (i-SPOC) who will inform EMA about the supply and availability of critical medicines identified in the context of a ‘public health emergency’ or a ‘major event’...
by In2Pharma | Jul 5, 2022 | News
Europe The Commission Regulation (EU) 2022/860 amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards monacolins from red yeast rice has been published on 2nd June 2022. This Regulation entered into force on 22nd...